229 related articles for article (PubMed ID: 36112929)
1. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
[TBL] [Abstract][Full Text] [Related]
2. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
[No Abstract] [Full Text] [Related]
4. De Novo CD5
Xu Y; Sun W; Li F
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
6. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study.
Sang W; Ma Y; Wang X; Ma Y; Shen Z; Gu W; Wang F; Ye J; Zhang C; Miao Y; Xu C; Liu Q; Li B; Tu J; Wang C; Shi Y; Sun S; Yan D; Song X; Sun C; Shao Y; Xu L; Li Z; Ma D; Xu K; Young KH; Liu H
Am J Surg Pathol; 2022 Nov; 46(11):1533-1544. PubMed ID: 36006771
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
9. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
Ma S; Zhang B; Lu T; Li D; Li T; Shen Z; He C; Wang Y; Li B; Zhang H; Gu W; Wang C; Ye J; Zhu T; Miao Y; Wang L; Huang S; Liu Q; Sang W;
Cancer; 2022 Oct; 128(19):3487-3494. PubMed ID: 35932292
[TBL] [Abstract][Full Text] [Related]
10. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K
Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
12. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
13. CD5
Lu TX; Wu S; Zhou XY; Zhang Y; Hong TT; Cai DY; Hua HY; Qi XW; Wu XH
Exp Mol Pathol; 2020 Feb; 112():104326. PubMed ID: 31706988
[TBL] [Abstract][Full Text] [Related]
14. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
17. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
Miyazaki K; Yamaguchi M; Suzuki R; Kobayashi Y; Maeshima AM; Niitsu N; Ennishi D; Tamaru JI; Ishizawa K; Kashimura M; Kagami Y; Sunami K; Yamane H; Nishikori M; Kosugi H; Yujiri T; Hyo R; Katayama N; Kinoshita T; Nakamura S
Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
[TBL] [Abstract][Full Text] [Related]
19. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
